Research programme: anti-hepatitis C virus monoclonal antibodies - GENimmune

Drug Profile

Research programme: anti-hepatitis C virus monoclonal antibodies - GENimmune

Alternative Names: ED 004; GNI 104; HCV hu mAbs - GENimmune

Latest Information Update: 14 Oct 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GENimmune
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 12 Feb 2008 Discontinued - Preclinical for Hepatitis C in Belgium (Parenteral)
  • 11 Dec 2007 A lead monoclonal antibody receives orphan drug status from the European Commission for the prevention of hepatitis C virus re-infection after liver transplantation
  • 28 Nov 2007 This programme is available for licensing (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top